Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:137994
Structure:
Synonyms:
1-Hydroxy-2,2,6,6-tetramethyl-4-piperidinol
1-Oxyl-2,2,6,6-tetramethyl-4-piperidinol
1-Piperidinyloxy, 4-hydroxy-2,2,6,6-tetramethyl-
105269-77-0
119227-61-1
13075-58-6
176141_ALDRICH
2,2,4,4-Tetramethyl-4-piperidinol N-oxide
2,2,6,6-Tetramethyl-4-hydroxypiperidin-1-oxyl
2,2,6,6-Tetramethyl-4-hydroxypiperidine 1-oxide
2,2,6,6-tetramethyl-4-hydroxypiperidine-1-oxyl
2,2,6,6-Tetramethyl-4-hydroxypiperidinooxy
2,2,6,6-Tetramethyl-4-hydroxypiperidinooxy radical
2,2,6,6-Tetramethyl-4-hydroxypiperidyl 1-oxyl
2,2,6,6-Tetramethyl-4-oxypiperidine-1-oxyl
2,2,6,6-Tetramethyl-4-piperidinol 1-oxide
2,2,6,6-Tetramethyl-4-piperidinol 1-oxyl
2,2,6,6-Tetramethyl-4-piperidinol N-oxyl
2,2,6,6-Tetramethyl-4-piperidinol nitroxide
2,2,6,6-Tetramethyl-4-piperidinol-1-oxy
2,2,6,6-Tetramethyl-4-piperidinol-N-oxyl
2,2,6,6-Tetramethyl-4-piperindiol 1-oxyl
2,2,6,6-Tetramethylpiperidine-N-oxyl-4-ol
2,2,6,6-Tetramethylpiperidinol-4-oxyl-1
2226-96-2
3174-32-1
3637-10-3
38854-37-4
4-hydroxy tempo
4-hydroxy-1-oxyl-2,2,6,6-tetramethylpiperidine
4-Hydroxy-2,2,6,-tetramethylpiperidyl-1-oxy
4-Hydroxy-2,2,6,-tetramethylpiperidyl-1-oxyl
4-hydroxy-2,2,6,6-tetramethyl piperidinyloxy
4-hydroxy-2,2,6,6-tetramethyl piperidinyloxy 2226-96-2
4-Hydroxy-2,2,6,6-tetramethyl piperidinyloxy free radical
4-hydroxy-2,2,6,6-tetramethyl piperidinyloxy freeradical
4-hydroxy-2,2,6,6-tetramethyl piperidinyloxyfree radical
4-Hydroxy-2,2,6,6-tetramethyl-1-piperidinyloxy
4-hydroxy-2,2,6,6-tetramethyl-1-piperidinyloxy, free radical
4-hydroxy-2,2,6,6-tetramethyl-piperidinooxy
4-hydroxy-2,2,6,6-tetramethyl-piperidinooxy, free radical
4-Hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl
4-Hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl
4-Hydroxy-2,2,6,6-tetramethylpiperidine N-oxide
4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl
4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxy
4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl
4-Hydroxy-2,2,6,6-tetramethylpiperidinooxy
4-Hydroxy-2,2,6,6-tetramethylpiperidinooxy radical
4-Hydroxy-2,2,6,6-tetramethylpiperidinooxyl
4-Hydroxy-2,2,6,6-tetramethylpiperidinoxy
4-hydroxy-2,2,6,6-tetramethylpiperidinoxy radical
4-Hydroxy-2,2,6,6-tetramethylpiperidinoxyl
4-hydroxy-2,2,6,6-tetramethylpiperidinyl-1-oxy
4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy
4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical
4-hydroxy-2,2,6,6-tetrmethylpiperidinyloxy
4-Hydroxy-TEMPO
4-Hydroxy-TEMPO, free radical
4-Oxypiperidol
68541-96-8
70939-25-2
900145-52-0
908588-62-5
AC1L3BTY
C001803
C9H19NO2
CCRIS 4555
CHEMBL607023
EINECS 218-760-9
H0865
HOTMP
HyTEMPO
LS-117287
MolPort-000-156-390
N-Oxyl-2,2,6,6-tetramethylpiperidine
NCGC00248196-01
nitroxide 4-hydroxy-2,2,6,6-tetramethylpiperidinyl-N-oxyl
Nitroxyl 2
nitroxyl-2 (2,2,6,6-tetramethyl 4-oxypiperidine)-1-oxyl
NR 1
NSC 142784
PIPERIDINOOXY, 4-HYDROXY-2,2,6,6-TETRAMETHYL-
ST065678
Tanol
Tempol
Tetramethylpiperidino-N-oxyl
Tetramethylpiperidinol N-oxyl
TMPN
TPL cpd

Target

show target details
Uniprot ID:DUOX1_RAT
Synonyms:
Dual oxidase 1
EC-Numbers:1.11.1.-
1.6.3.1
Organism:Rat
Rattus norvegicus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

16788136
Endothelin-A and -B receptors, superoxide, and Ca2+ signaling in afferent arterioles.. Susan K Fellner; William Arendshorst (2007) American journal of physiology. Renal physiology display abstract
It is unknown if endothelin-A and -B receptors (ET(A)R and ET(B)R) activate the production of superoxide via NAD(P)H oxidase and subsequently stimulate the formation of cyclic adenine diphosphate ribose (cADPR) in afferent arterioles. Vessels were isolated from rat kidney and loaded with fura 2. Endothelin-1 (ET-1) rapidly increased cytosolic Ca(2+) concentration ([Ca(2+)](i)) by 303 nM. The superoxide dismutase mimetic tempol, the NAD(P)H oxidase inhibitor apocynin, and nicotinamide, an inhibitor of ADPR cyclase, diminished the response by approximately 60%. The ET(B)R agonist sarafotoxin 6c (S6c) increased peak [Ca(2+)](i) by 117 nM. Subsequent addition of ET-1 in the continued presence of S6c caused an additional [Ca(2+)](i) peak of 225 nM. Neither nicotinamide or 8-bromo- (8-Br) cADPR nor apocynin decreased the [Ca(2+)](i) response to S6c, but inhibited the subsequent [Ca(2+)](i) response to ET-1. The ET(B)R blockers BQ-788 and A-192621 prevented the S6c [Ca(2+)](i) peak and reduced the ET-1 response by more than one-half, suggesting an ET(B)R/ET(A)R interaction. In contrast, the ET(A)R blocker BQ-123 had no effect on the S6c [Ca(2+)](i) peak and obliterated the subsequent ET-1 response. ET-1 immediately stimulated superoxide formation (measured with TEMPO-9-AC, 68 arbitrary units) that was inhibited 95% by apocynin or diphenyl iodonium. S6c or IRL-1620 increased superoxide by 8% of that caused by subsequent ET-1 addition. We conclude that ET(A)R activation of afferent arterioles increases the formation of superoxide that accounts for approximately 60% of subsequent Ca(2+) signaling. ET(B)R activation appears to result in only minor increases in superoxide production. Nicotinamide and 8-Br-cADPR results suggest that ET-1 (and primarily ET(A)R) causes the activation of vascular smooth muscle cell-ADPR cyclase.